Investing.com - Financial Markets Worldwide

AbCellera soars as revenue more than doubles estimates

Published 07/08/2025, 22:16
AbCellera soars as revenue more than doubles estimates
ABCL
2.91%

Investing.com -- AbCellera Biologics Inc (NASDAQ:ABCL) reported second-quarter revenue that more than doubled analyst expectations, sending shares soaring 10.5% as the company also announced it has officially transitioned to a clinical-stage biotechnology firm.

The antibody discovery platform company posted revenue of $17.1 million for the second quarter of 2025, significantly exceeding the analyst consensus estimate of $7.45 million and marking a 134% increase from $7.3 million in the same quarter last year. AbCellera reported a quarterly loss of -$0.12 per share, better than analysts’ expectations of -$0.14 per share and an improvement from the -$0.13 per share loss reported in Q2 2024.

The company announced it has begun dosing participants in a Phase 1 clinical trial of ABCL635, a potential treatment for menopause-related hot flashes, marking AbCellera’s transition to a clinical-stage biotechnology company. The firm also initiated a Phase 1 trial for ABCL575, targeting atopic dermatitis.

"In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "With over $750 million in available liquidity, we are well-positioned to continue to execute our strategy."

AbCellera reported a net loss of $34.7 million for the quarter, compared to a net loss of $36.9 million in the same period last year. Research and development expenses decreased slightly to $39.2 million from $40.9 million YoY, with the company noting a greater proportion is now directed toward internal programs.

The company maintains a strong financial position with $580 million in cash, cash equivalents, and marketable securities, plus approximately $173 million in available non-dilutive government funding, bringing total available liquidity to approximately $753 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.